Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Nirogacestat (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- 03 Apr 2019 Planned End Date changed from 12 Oct 2019 to 12 Oct 2020.
- 16 Nov 2018 Results assessing efficacy of PF 3084014 in desmoid tumors, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 19 Apr 2018 Planned primary completion date changed from 30 Dec 2018 to 12 Oct 2019.